Daniel T. Scavilla is the President and CEO of Globus Medical Inc., a company he joined in 2015. With a solid background in finance, Scavilla earned a B.S. from LaSalle University and an M.B.A. from Temple University. Before becoming CEO...

Daniel T. Scavilla is the President and CEO of Globus Medical Inc., a company he joined in 2015. With a solid background in finance, Scavilla earned a B.S. from LaSalle University and an M.B.A. from Temple University. Before becoming CEO in April 2022, he held several key roles at Globus, including Executive Vice President and Chief Commercial Officer. Prior to that, he spent 28 years at Johnson & Johnson, where he worked in various financial positions and developed substantial expertise in medical devices. Scavilla’s leadership came at a time when Globus needed to navigate a competitive market in the medical technology field. His total compensation for 2022 was about $2.5 million, with a significant portion coming from vested stock options, reflecting his alignment with shareholder interests.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Globus Medical CEOs

G

Daniel T. Scavilla

CEO of Globus Medical

Education

B.S. from LaSalle University, M.B.A. from Temple University

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

January 1, 1965 - 60 years ago

CEO of Globus Medical for

3 years 0 months (Apr 2022 - Present)

Previous Experience

Executive Vice President and Chief Commercial Officer since February 2019; Chief Financial Officer from May 2015 to August 2019.

Rivals

Competitors/colleagues of Daniel T. Scavilla

Holdings

See how much did Daniel T. Scavilla make over time.

Daniel T. Scavilla has a notable investment in Globus Medical, reflecting his commitment to the company. In 2022, his vested stock options were valued at approximately $2.4 million, a significant boost from prior years as he transitioned into his current...

Daniel T. Scavilla has a notable investment in Globus Medical, reflecting his commitment to the company. In 2022, his vested stock options were valued at approximately $2.4 million, a significant boost from prior years as he transitioned into his current leadership role. Scavilla’s wealth in the company's stock indicates strong confidence in its future and aligns his interests with those of other investors. The fluctuations in his holdings highlight his focus on driving the company's performance and creating value for shareholders. As he leads Globus Medical, his commitment to the company is evident through his substantial share ownership, particularly during his rise to the CEO position in 2022. In previous years, the value of his holdings has varied with stock performance, but his recent options vesting marks a strong period for him personally and for the company overall.

Total Stock Sold

$18.33M

GMED

$18.33M

300,000 GMED shares

What if they kept their stock?

If Daniel T. Scavilla didn't sell their stock, today they would have:
Extra GMED300,000 shares worth $13.62M.
This is -25.66% and $4.70M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Daniel T. Scavilla.

GMED

$7.87M

GMED at $78.69/share

Jul 2, 2021

Sale

GMED

$5.51M

GMED at $55.09/share

May 21, 2020

Sale

GMED

$5.00M

GMED at $50.00/share

Apr 9, 2018

Sale

Compensation History

See how much did Daniel T. Scavilla make over time.

In 2022, Daniel T. Scavilla’s total compensation amounted to approximately $2.5 million. This package included a base salary of $437,064, a bonus tied to performance metrics reaching $194,117, and over $2.4 million from vested stock options. The bonus system Scavilla is part of rewards both company achievements and individual performance, ensuring he is encouraged to lead Globus effectively while aligning his success with that of the company. His compensation is structured to attract and retain top talent, and it reflects the company's goals to boost revenue and shareholder value. This mix of salary, performance bonuses, and stock-based compensation illustrates standard practices in the industry to motivate CEO performance, especially in a changing market like medical technology.

Year

2022

Total Compensation

$3.11M

Salary

$437.06K

Board Justification

The compensation philosophy is aimed at attracting and retaining talented leaders, with a focus on performance-based compensation that aligns with company performance and shareholder value.

Bonus

$194.12K

Board Justification

The bonus is based on the achievement of company and individual performance targets, with the final amount determined by the Compensation Committee.

Other

$33.28K

Board Justification

This includes other compensation such as a car allowance and health benefits.

Restricted Stock

$2.45M(2.45M stock options)

Board Justification

The stock options granted to Mr. Scavilla that vested in 2022, reflecting the fair market value at the time of vesting.

Performance Metrics

The performance metrics for determining the compensation included total company revenue achievement.

Other Globus Medical CEOs

Here are other CEOs of Globus Medical

David M. Demski

Ex-CEO of Globus Medical

August 2017 - April 2022